AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment

AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now.

AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment

On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic lymphocytic leukemia (CLL).

The trial results also affirm venetoclax plus obinutuzumab’s ability to improve progression-free survival (PFS) compared to chlorambucil plus obinutuzumab. Consequently, it affirms the candidate drug’s potential in patients living with difficult-to-cure blood cancers.

The positive clinical trial results come on the heels of AbbVie reiterating its commitment to shareholder value by declaring a $ 1.73-per-share quarterly dividend. The dividend is to be paid on August 14, 2026, to shareholders of record as of July 15, 2026.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines and therapies to treat complex, critical health issues worldwide. Spun off from Abbott in 2013, the company treats millions of people globally across five main areas of medicine.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 UK Stocks with the Highest Dividends and 10 Best Falling Stocks to Invest In According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1